Aren't you amazed about how fast the world has come together to find a collective solution for COVID-19? We have learned in the past months that we can compress the traditional vaccine paradigm, which is between 5 to 10 years to just 4 to 18 months.
The tremendous impact of the COVID crisis has significantly raised the global expectations and appreciation for innovation, digital, and excellence, which leads us to the question: what will the new normal be?
That's why there has never been a better time to connect, even virtually, in order to shape the transformation of the pharmaceutical industry with knowledge and expertise across the entire lifecycle.
Join us at the 2020 ISPE Biotechnology Virtual Conference on 7–8 October to hear from the experts as they discuss:
Your event experience includes access to two ATMP-focused workshops where you will discuss, debate, and identify potential deliverables.
Included in your conference registration are exclusive facilities tour of Produlab Pharma (PP), Catalent, and Takeda.
Designed to be highly interactive and hosted on a state-of-the-art digital platform, the 2020 ISPE Biotechnology Virtual Conference delivers the same high-quality content and premier engagement opportunities that you expect from this signature ISPE event.
I truly believe you and your team will find this event invaluable based on the opportunity for regulatory duty and comprehensive agenda addressing timely, industry-critical topics.
In addition, we are pleased to announce pricing for the 2020 ISPE Biotechnology Virtual Conference ranging from € 35 to € 495.
I look forward to seeing you there also for virtual networking!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...